Source-grounded facts extracted from Generate Biomedicines, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Generate Biomedicines, Inc. reported the first quarter ended March 31, 2026 results: revenue $7.2 million, net income Net loss was $61.7 million.
“its operations into the first half of 2028. Generate expects to require additional capital to support long-term operations. Revenue for the quarter ended March 31, 2026, was $7.2 million, compared with $8.8 million for the same period in 2025. This revenue reflects developments in the ongoing Amgen and Novartis research programs. Research and development expenses”
Governance Changes
Generate Biomedicines, Inc.: Amended and restated bylaws to establish procedures for stockholder meetings, advance notice proposals, and conform to amended certificate (effective 2026-03-02).
“The Amended and Restated Bylaws amend and restate the Company’s bylaws in their entirety to, among other things: (i) establish procedures for the Company’s stockholders to take formal actions at meetings of stockholders; (ii) establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of the Company’s stockholders, including proposed nominations of persons for election to the Board; and (iii) conform to the amended provisions of the Amended and Restated Certificate.”
Governance Changes
Generate Biomedicines, Inc.: Amended and restated certificate of incorporation to authorize 500M common shares, eliminate references to previous preferred series, authorize 10M undesignated preferred shares, and eliminate stockholder ability to act by written consent and call special meetings (effective 2026-03-02).
“The Amended and Restated Certificate amends and restates the Company’s existing amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series; and (iv) eliminate the ability of the Company’s stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.